In today’s recent session, 1.18 million shares of the Cellectar Biosciences Inc (NASDAQ:CLRB) have been traded, and its beta is 0.98. Most recently the company’s share price was $0.32, and it changed around $0.02 or 5.47% from the last close, which brings the market valuation of the company to $14.58M. CLRB at last check was trading at a discount to its 52-week high of $4.45, offering almost -1290.62% off that amount. The share price’s 52-week low was $0.22, which indicates that the recent value has risen by an impressive 31.25% since then. We note from Cellectar Biosciences Inc’s average daily trading volume that its 10-day average is 1.47 million shares, with the 3-month average coming to 2.70 million.
Cellectar Biosciences Inc stock received a consensus recommendation rating of Overweight, based on a mean score of 1.50. If we narrow it down even further, the data shows that 0 out of 4 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 1 recommended CLRB as a Hold, whereas 1 deemed it a Buy, and 0 rated it as Underweight.
Cellectar Biosciences Inc (NASDAQ:CLRB) trade information
Instantly CLRB has been showing a green trend so far today with a performance of 5.47% on intraday trading today. The performance over the last five days has remained in the green territory. The rise to weekly highs of 0.3300 on recent trading dayincreased the stock’s daily price by 3.03%. The company’s shares are currently up 5.79% year-to-date, but still up 20.73% over the last five days. On the other hand, Cellectar Biosciences Inc (NASDAQ:CLRB) is 1.70% up in the 30-day period. We can see from the shorts that 1.84 million shares have been sold at a short interest cover period of 8.34 day(s).
The consensus price target as assigned by Wall Street analysts is $12, which translates to bulls needing to increase their stock price by 97.33% from its current value. Analyst projections state that CLRB is forecast to be at a low of $12 and a high of $12.
Cellectar Biosciences Inc (CLRB) estimates and forecasts
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 41.77%. Cellectar Biosciences Inc earnings are expected to increase by 48.15% in 2025, but the outlook is positive 32.07% per year for the next five years.
CLRB Dividends
Cellectar Biosciences Inc’s next quarterly earnings report is expected to be released in March.
Cellectar Biosciences Inc (NASDAQ:CLRB)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 2.84% of Cellectar Biosciences Inc shares, and 34.55% of them are in the hands of institutional investors. The stock currently has a share float of 35.56%.
Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund were the top two Mutual Funds as of Sep 30, 2024. The former held 1.07 shares worth $0.34 million, making up 2.33% of all outstanding shares. On the other hand, Vanguard Extended Market Index Fund held roughly 568.75 shares worth around $0.18 million, which represents about 1.23% of the total shares outstanding.
